Cargando…
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
PURPOSE: Novel pharmaceutical treatments reducing cardiovascular events in dyslipidaemia patients must demonstrate clinical efficacy and cost-effectiveness to promote long-term adoption by patients, physicians, and insurers. OBJECTIVE: To assess the cost-effectiveness of statin monotherapy compared...
Autores principales: | Michaeli, Daniel Tobias, Michaeli, Julia Caroline, Boch, Tobias, Michaeli, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397126/ https://www.ncbi.nlm.nih.gov/pubmed/35015186 http://dx.doi.org/10.1007/s10557-021-07310-y |
Ejemplares similares
-
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
por: Michaeli, Daniel Tobias, et al.
Publicado: (2023) -
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022) -
Testicular cancer follow-up costs in Germany from 2000 to 2015
por: Michaeli, Thomas, et al.
Publicado: (2021) -
Advances in cancer therapy: clinical benefit of new cancer drugs
por: Michaeli, Daniel Tobias, et al.
Publicado: (2023) -
Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)